Literature DB >> 3490468

Ciprofloxacin in acute exacerbations of chronic bronchitis.

J A Hoogkamp-Korstanje, S J Klein.   

Abstract

Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days. The short-term response rate was 97% (cure 70.6%, improvement 26.4%) and failure 3%; the long-term response rate (six months follow-up) was 73.5%. Predominant initial pathogens were Haemophilus influenzae and Streptococcus pneumoniae, mostly in pure cultures. All sputum cultures except those with Str. pneumoniae became negative on the third day of treatment. Apart from a slower clearance of pneumococci from the sputum there were no significant differences in responses between pneumococcal and Haemophilus infections during and after therapy. Peak serum levels at 2 h after administration were 3.8 +/- 1.7 mg/l, half life was 3 h; peak sputum levels at 4 h were 1.3 +/- 0.95 mg/l. The serum-sputum penetration was 49.7% measured by AUC values. Mild adverse gastrointestinal effects were noticed in five patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490468     DOI: 10.1093/jac/18.3.407

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Ciprofloxacin in general practice.

Authors:  P M Donaldson; A P Pallett; M P Carroll
Journal:  BMJ       Date:  1994-05-28

2.  Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

Authors:  M E Klepser; E J Ernst; C R Petzold; P Rhomberg; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.

Authors:  P Saux; C Martin; M N Mallet; L Papazian; B Bruguerolle; P De Micco; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.

Authors:  A Watanabe
Journal:  Infection       Date:  1991       Impact factor: 3.553

6.  Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.

Authors:  M C Sullivan; B W Cooper; C H Nightingale; R Quintiliani; M T Lawlor
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 7.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

8.  Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin.

Authors:  J A Hoogkamp-Korstanje; S J Klein
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.